title: D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis.
abstract: OBJECTIVE
  The relationship between clinically effective antipsychotic drugs in obsessive-compulsive disorders (OCD) and binding affinities to cloned dopamine and serotonin receptor subtypes was analyzed in an effort to clarify the contribution of individual receptor subtypes to medication response.
  
  
  METHODS
  Meta-analysis was used to update previous meta-analyses of effectiveness data of add-on antipsychotic drugs to selective serotonin reuptake inhibitors (SSRIs) in OCD. Twelve previously analyzed randomized controlled trials (RCTs) and one new RCT were included. We performed a metaregression using a mixed-effect model to examine the association between antipsychotic's effectiveness and receptor affinity.
  
  
  RESULTS
  A total of 5 treatment arms obtained from 13 RCTs (431 patients) were included in our study. The results of our metaregression showed a significant association between D2 and D3 dopamine receptor affinities and effectiveness in OCD (respectively, slope = -0.36, p = 0.01; and slope = -0.50, p = 0.01) whereas other dopamine receptors and serotonin receptors were not significantly associated.
  
  
  CONCLUSIONS
  These observations suggest that increasing D2 and D3 dopamine receptor binding affinities enhances antipsychotics' effectiveness in obsessive-compulsive disorders.
authors.affiliation: INSERM U1061, Université Montpellier 1, Service Universitaire de Psychiatrie Urgence et Post-urgence, CHU Montpellier, Montpellier, 34000, France.
authors.forename: Deborah
authors.initials: D
authors.lastname: Ducasse
authors.forename: Laurent
authors.initials: L
authors.lastname: Boyer
authors.forename: Pierre
authors.initials: P
authors.lastname: Michel
authors.forename: Anderson
authors.initials: A
authors.lastname: Loundou
authors.forename: Alexandra
authors.initials: A
authors.lastname: Macgregor
authors.forename: Jean-Arthur
authors.initials: JA
authors.lastname: Micoulaud-Franchi
authors.forename: Philippe
authors.initials: P
authors.lastname: Courtet
authors.forename: Mocrane
authors.initials: M
authors.lastname: Abbar
authors.forename: Marion
authors.initials: M
authors.lastname: Leboyer
authors.forename: Guillaume
authors.initials: G
authors.lastname: Fond
mesh_terms: D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D050637:Receptors, Dopamine D3 / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D011985:Receptors, Serotonin